Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Radiat Oncol. 2022 May 21;17(1):100. doi: 10.1186/s13014-022-02065-8.
We investigated the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) in patients with locally advanced rectal cancer (LARC) and whether modifiable factors in radiotherapy (RT) influenced the NLR.
Data of 1386 patients who were treated with neoadjuvant RT and concurrent or sequential chemotherapy for LARC between 2006 and 2019 were evaluated. Most patients (97.8%) were treated with long-course RT (LCRT; 50-50.4 Gy in 25-28 fractions) using three-dimensional conformal radiotherapy (3D-CRT) (n = 851) or helical tomotherapy (n = 504), and 30 patients underwent short-course RT (SCRT; 25 Gy in 5 fractions, followed by XELOX administration for 6 weeks). Absolute neutrophil and lymphocyte counts were obtained at initial diagnosis, before and during the preoperative RT course, and after preoperative concurrent chemoradiotherapy. The primary endpoint was distant metastasis-free survival (DMFS).
The median follow-up time was 61.3 (4.1-173.7) months; the 5-year DMFS was 80.1% and was significantly associated with the NLR after RT but not before. A post-RT NLR ≥ 4 independently correlated with worse DMFS (hazard ratio, 1.42; 95% confidence interval, 1.12-1.80), along with higher ypT and ypN stages. Post-RT NLR (≥ 4) more frequently increased following LCRT (vs. SCRT, odds ratio [OR] 2.77, p = 0.012) or helical tomotherapy (vs. 3D-CRT, OR 1.29, p < 0.001).
Increased NLR after neoadjuvant RT is associated with increased distant metastasis risk and poor survival outcome in patients with LARC. Moreover, high NLR following RT is directly related to RT fractionation, delivery modality, and tumor characteristics. These results are hypothesis-generating only, and confirmatory studies are required.
我们研究了中性粒细胞与淋巴细胞比值(NLR)对局部晚期直肠癌(LARC)患者的预后影响,以及放疗(RT)中是否存在可改变的因素会影响 NLR。
评估了 2006 年至 2019 年间接受新辅助 RT 联合同期或序贯化疗治疗的 1386 例 LARC 患者的数据。大多数患者(97.8%)接受长程 RT(LCRT;50-50.4Gy,25-28 次分割),使用三维适形放疗(3D-CRT)(n=851)或螺旋断层放疗(n=504),30 例患者接受短程 RT(SCRT;25Gy,5 次分割,随后 XELOX 治疗 6 周)。在初始诊断、术前 RT 期间和术前同期放化疗前后获得绝对中性粒细胞和淋巴细胞计数。主要终点是无远处转移生存(DMFS)。
中位随访时间为 61.3(4.1-173.7)个月;5 年 DMFS 为 80.1%,与 RT 后的 NLR 显著相关,但与 RT 前的 NLR 无关。RT 后 NLR≥4 与更差的 DMFS 独立相关(风险比,1.42;95%置信区间,1.12-1.80),同时伴有更高的 ypT 和 ypN 分期。与 SCRT(比值比 [OR] 2.77,p=0.012)或螺旋断层放疗(OR 1.29,p<0.001)相比,LCRT 后 NLR(≥4)更频繁地增加。
新辅助 RT 后 NLR 的增加与 LARC 患者的远处转移风险增加和生存结局不良相关。此外,RT 后 NLR 升高与 RT 分割、放疗方式和肿瘤特征直接相关。这些结果仅为假说产生,需要进一步的验证性研究。